“Interpretation: Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19…
Discussion: We have shown that the inhaled glucocorticoid budesonide, given for a short duration, might be an effective treatment of early COVID-19 in adults. This effect, with a relative reduction of 91% of clinical deterioration is equivalent to the efficacy seen after the use of COVID-19 vaccines and greater than that reported in any treatments used in hospitalised patients and patients with severe COVID-19.”
All content on this site: Copyright © 2023 Elsevier Ltd., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.For all open access content, the Creative Commons licensing terms apply.